Advertisement

Reactions Weekly

, Volume 1780, Issue 1, pp 274–274 | Cite as

Nivolumab

Various toxicities: 11 case reports
Case report
  • 45 Downloads

Reference

  1. Hori R, et al. Real-world outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic head and neck carcinoma. Cancers 11: 1317, No. 9, Sep 2019. Available from: URL: http://doi.org/10.3390/cancers11091317 - JapanCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations